US Exchange Filings

GeoVax Reshuffles Leadership With Fractional CFO Appointment and CMO Termination

GeoVax is reshaping its leadership: its CFO has departed, a fractional finance chief is taking over, the interim CEO is formalizing a paid consulting arrangement, and the chief medical officer has been terminated. Investors will be watching as the company searches for permanent leadership.

GeoVax Labs has reshuffled its senior leadership, with its chief financial officer resigning, a fractional CFO taking over, and its interim chief executive formalizing a paid consulting arrangement. The company also terminated its chief medical officer, effective immediately, on November 17.

The changes leave GeoVax’s top finance and executive roles with interim or consultant arrangements while it searches for permanent leadership.

Key details

  • CFO departure and replacement: Mark W. Reynolds resigned as CFO, corporate secretary and from his other officer roles at GeoVax and its subsidiaries, effective at 5 p.m. Eastern on November 13. He also had been the company’s principal financial officer and principal accounting officer.

  • Fractional CFO: The board appointed Anna Skowron as CFO, effective November 16. She also assumes the principal financial and accounting officer responsibilities. Skowron works through BPC Consulting, a firm that provides financial and accounting services, and will serve GeoVax on a fractional basis.

  • CFO responsibilities and pay: Skowron will oversee accounting and financial reporting, including preparation of the company’s periodic reports, and report to the CEO and audit committee chair. GeoVax will pay BPC $10,000 a month, plus applicable taxes. BPC may also receive a performance-based bonus for completing the annual report and year-end audit, with the amount and terms to be agreed before the audit begins. Skowron is eligible to participate in the company’s management compensation and equity plans.

  • CFO agreement terms: The engagement began November 16 and continues until either party ends it with 90 days’ written notice. If GeoVax terminates without providing that notice, it must pay fees based on BPC’s average monthly invoices over the prior three months for the notice period. The company will reimburse reasonable business expenses and provide Skowron with officer indemnification.

  • Skowron’s background: She has worked as a consultant to public and private companies on CFO services, accounting, financial reporting, financings and strategic transactions. She has held several fractional or interim CFO roles since 2025 and has been a director of BPC Consulting since September 2025.

  • Interim CEO’s consulting arrangement: Tyler O’Brien, whom the board appointed interim CEO and chairman earlier in November, signed a consulting agreement with GeoVax on November 16, effective November 5. He serves as CEO as a non-employee consultant until the company appoints or designates a permanent principal executive officer.

  • CEO pay and agreement terms: GeoVax will pay O’Brien $15,000 a month. The board or its compensation committee may periodically review and adjust the rate, but cannot reduce it without his written consent. He is eligible for the company’s incentive, bonus and equity plans, and the agreement provides for expense reimbursement and indemnification. Either side may terminate with 90 days’ written notice; if the company ends the agreement without that notice, it must pay the fees due for the notice period at the then-current monthly rate.

  • Prior CEO claims: O’Brien waived claims under prior agreements with GeoVax, while retaining rights to indemnification, expense advances and exculpation as an officer or director, as well as previously granted equity awards.

  • Chief medical officer: GeoVax terminated Kelly T. McKee as chief medical officer effective immediately on November 17. No reason was provided.

The arrangements put GeoVax’s finance and executive leadership in consultant-based roles: Skowron is a fractional CFO, and O’Brien is serving as interim CEO. The company has not named a permanent CEO, and the CFO agreement has no fixed end date.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.